Research
Hormonal
High systolic blood pressure (SBP) is a leading metabolic risk factor globally, contributing to 7.8% of total disability-adjusted life-years (DALYs) in 2021, with an increasing annual exposure rate of 1.8%.
High blood pressure is a major driver of global disease burden. Regular monitoring and management are crucial for long-term health.
StrongSupportsVERY_HIGH confidence
Among the specific risk factors analysed for this study, particulate matter air pollution was the leading contributor to the global disease burden in 2021, contributing 8·0% (95% UI 6·7–9·4) of total DALYs, followed by high systolic blood pressure (SBP; 7·8% [6·4–9·2])...
Why this rating
Based on 54,561 distinct data sources and systematic meta-regression.
Source
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Michael Bräuer et al. · The Lancet · 2024
DOI 10.1016/s0140-6736(24)00933-4
Meta-analysis · 54561 studiesCited 2,427×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High body-mass index (BMI) is a significant metabolic risk factor with increasing exposure rates (1.8% annually) and a 15.7% rise in age-standardized DALY rates from 2000 to 2021.Strong
- Particulate matter air pollution is the leading contributor to global disease burden, accounting for 8.0% of total DALYs in 2021.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →